Skip to content

Study · Randomized controlled trial · 1994

5 results

A prospective randomized comparison of two gonadotrophin-releasing hormone agonists, nafarelin acetate and buserelin acetate, in in-vitro fertilization-embryo transfer.

Goldman JA, Dicker D, Feldberg D, Ashkenazi J, Voliowich I

Human reproduction (Oxford, England)1 Feb 1994Cited by 9 (Europe PMC)

PMID8027276 (opens in a new tab)DOI10.1093/oxfordjournals.humrep.a138486 (opens in a new tab)PepBankPUB-08027276
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women undergoing IVF, cycle cancellation, oocyte yield, fertilization and cleavage did not differ significantly between nafarelin and buserelin.

    In plain wordsIn women undergoing IVF, cycle cancellation, oocyte yield, fertilization and cleavage did not differ significantly between nafarelin and buserelin.

    Peptide
    Nafarelin
    Outcome
    No significant changeCycle cancellation, oocyte yield, fertilization and cleavage
    Study

    n: not reported in source

    Comparator
    Buserelin acetate
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated · nasal sprayAs given in this study (human).

    Source sentences

    Summary
    There was no significant difference in patient response, measured by cycle cancellation, number of oocytes retrieved, fertilization rate and cleavage rate.
    2 context sentences
    Title · context
    A prospective randomized comparison of two gonadotrophin-releasing hormone agonists, nafarelin acetate and buserelin acetate, in in-vitro fertilization-embryo transfer.
    Summary · context
    Therapy was used in a long protocol in the luteal phase in two groups of women with similar aetiology of infertility.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In women undergoing IVF, pregnancy rates per cycle were similar with nafarelin and buserelin, at 22% and 24%.

    In plain wordsIn women undergoing IVF, pregnancy rates per cycle were similar with nafarelin and buserelin.

    Peptide
    Nafarelin
    Outcome
    DecreasePregnancy per cycle
    Study

    n: not reported in source

    Comparator
    Buserelin acetate
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated · nasal sprayAs given in this study (human).

    Measurements

    Pregnancy rate
    22%
    nafarelin per cycle
    Pregnancy rate
    24%
    buserelin per cycle

    Source sentences

    Summary
    Pregnancy rates were similar in nafarelin acetate and buserelin acetate treated women, namely 22% and 24% pregnancies per cycle, and 28.8% and 32.1% pregnancies per transfer, respectively.
    2 context sentences
    Title · context
    A prospective randomized comparison of two gonadotrophin-releasing hormone agonists, nafarelin acetate and buserelin acetate, in in-vitro fertilization-embryo transfer.
    Summary · context
    Therapy was used in a long protocol in the luteal phase in two groups of women with similar aetiology of infertility.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In women undergoing IVF, pregnancy rates per transfer were similar with nafarelin and buserelin, at 28.8% and 32.1%.

    In plain wordsIn women undergoing IVF, pregnancy rates per transfer were similar with nafarelin and buserelin.

    Peptide
    Nafarelin
    Outcome
    DecreasePregnancy per transfer
    Study

    n: not reported in source

    Comparator
    Buserelin acetate
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated · nasal sprayAs given in this study (human).

    Measurements

    Pregnancy rate
    28.8%
    nafarelin per transfer
    Pregnancy rate
    32.1%
    buserelin per transfer

    Source sentences

    Summary
    Pregnancy rates were similar in nafarelin acetate and buserelin acetate treated women, namely 22% and 24% pregnancies per cycle, and 28.8% and 32.1% pregnancies per transfer, respectively.
    2 context sentences
    Title · context
    A prospective randomized comparison of two gonadotrophin-releasing hormone agonists, nafarelin acetate and buserelin acetate, in in-vitro fertilization-embryo transfer.
    Summary · context
    Therapy was used in a long protocol in the luteal phase in two groups of women with similar aetiology of infertility.
  4. 04HumanRandomized controlled trialSafety outcome

    In women undergoing IVF, side effects were few and comparable with nafarelin and buserelin.

    In plain wordsIn women undergoing IVF, side effects were few and comparable with nafarelin and buserelin.

    Peptide
    Nafarelin
    Outcome
    Direction not reportedSide effects
    Study

    n: not reported in source

    Comparator
    Buserelin acetate
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · nasal sprayAs given in this study (human).

    Source sentences

    Summary
    Side-effects were few and comparable in both groups.
    2 context sentences
    Title · context
    A prospective randomized comparison of two gonadotrophin-releasing hormone agonists, nafarelin acetate and buserelin acetate, in in-vitro fertilization-embryo transfer.
    Summary · context
    Therapy was used in a long protocol in the luteal phase in two groups of women with similar aetiology of infertility.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In women undergoing IVF, nafarelin required significantly fewer human menopausal gonadotrophin ampoules than buserelin.

    In plain wordsIn women undergoing IVF, nafarelin required fewer human menopausal gonadotrophin ampoules than buserelin.

    Peptide
    Nafarelin
    Outcome
    DecreaseHuman menopausal gonadotrophin requirement
    Study

    n: not reported in source

    Comparator
    Buserelin acetate
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated · nasal sprayAs given in this study (human).

    Source sentences

    Summary
    The only difference noted was that women receiving nafarelin acetate required significantly fewer ampoules of human menopausal gonadotrophin, making a significant difference in the expense involved.
    2 context sentences
    Title · context
    A prospective randomized comparison of two gonadotrophin-releasing hormone agonists, nafarelin acetate and buserelin acetate, in in-vitro fertilization-embryo transfer.
    Summary · context
    Therapy was used in a long protocol in the luteal phase in two groups of women with similar aetiology of infertility.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.